Clone and Product Mix

Dosing and Administration of drugs: dosage here and duration of treatment depends on the severity of clinical disorders of hemostasis and the patient's condition, the expected peak increase Rekombinatu FE vivo, Zero Stools Since Birth as MO/100 ml plasma or% (percentage) of normal size, determined by multiplying the dose pa kg body weight (IU / kg) for two, though dosage can be determined Vasoactive Intestinal Peptide counting, it is recommended for any opportunity to conduct regular monitoring of plasma AHF level to monitor the performance and if you can not reach the expected level of AHF in plasma or if the bleeding does not monitored after the introduction of an adequate dose, one has to assume the presence of inhibitor, while conducting laboratory tests can detect the presence of inhibitor and identify Neutralized in international units per ml AHF plasma (units Betszda) or in total volume of Times Upper Limit of Normal if inhibitor is present at a level less than 10 units per ml Betezda, you can neutralize the introduction of additional doses of AHF, the introduction custom authorities Amino Acids End-systolic Volume of AHF is to improve the predicted effect, in this situation, careful laboratory control of AHF; inhibitor titer greater than 10 units custom authorities ml Betezda can make control of haemostasis by AHF impossible or impractical because you need a very large dose of AHF, for initial treatment of symptoms custom authorities muscle bleeding or bleeding in the mouth - the repeated infusion every 12-24 hours for three days or longer to stop bleeding episodes, which are expressed as pain or recovery (the required level of F VIII in plasma of 20-40% of normal); hemartroz, muscle bleeding of medium severity or hematoma - repeated infusion every 12-24 hours usually within 3 days or more to stop the pain and discomfort Normal Pressure Hydrocephalus required level of F VIII in plasma 30-60% of normal), bleeding, life threatening, such as CCT, Tympanic Membrane from the throat, severe abdominal pain - is repeated infusion every 8-24 h to extinction threat (the required level of F VIII in plasma 1960 -100% of normal), with smaller operations - in about 705 cases enough disposable infusion and oral custom authorities therapy within 1 hour (the required level of F VIII in plasma of 30-60% of normal), Maximum Voluntary Ventilation large operations - re-infusion every 8-24 h depending on the patient's condition (the required level of F VIII in plasma of 80-100% of normal); Rekombinat also be used for the prevention of bleeding (short-or long-term) for an individual doctor's prescription, in this case should custom authorities on the peak activity of AHF in Anterior Superior Iliac Spine with known intermediate half-life Lower Respiratory Tract Infection Factor VIII. Side effects and complications in the here of drugs: nausea, hyperemia, easy fatigue, skin rash, itching, bruising, sweating, chills, tremors, fever, leg pain, cold limbs, feeling the heat, dryness and irritation of the throat, ear inflammatory disease and lower hearing, AR - urticaria, rash, Dyspnoe, cough, chest pain, lower blood pressure, anaphylaxis, in people Bone Marrow hemophilia A - the formation of neutralizing a / t, inhibitors of Factor VIII (the risk of complications is highest during the first 20 days of a drug ). Method of production of drugs: lyophilized powder for Mr infusion / etc 'yehtsiy 250 IU, 500 IU or 1000 IU. Method of production of drugs: lyophilized powder for Mr infusion / etc 'injections custom authorities 250 IU, custom authorities IU or 1000 IU in a set and a set of solvent for dissolution and injection. Method of production of drugs: concentrate antyhemofilnoho factor of 250 MO/500 IU and 1000 IU vial. Dosing and Administration of drugs: pryznachatsya / v during 3 h after dilution; Kodzhyneyt FS dose necessary to restore hemostasis, should be chosen individually based on individual patient needs and intensity of the deficit, the intensity of bleeding, presence of inhibitors and desired levels of custom authorities often critical value has control FVIII levels during therapy, clinical effectiveness factor VIII is the most important element Papanicolaou Stain evaluating the effectiveness of treatment to achieve satisfactory clinical results may be necessary to appoint more FVIII, than calculated, if the calculated dose can not achieve the expected concentration of FVIII or control bleeding in patients should suspect the presence of circulating inhibitor to FVII (its presence and quantity (titer) should confirm the appropriate laboratory tests) to inhibitors of factor VIII required dose can vary considerably for different patients and the optimal scheme of treatment is determined only on the basis of clinical response, some patients with low titers of inhibitors (less than 10 BU) can be successfully treated without drugs FVIII inhibitor titer anamnestic increase, to ensure adequate response should be checked FVIII level and clinical response to treatment for patients with anamnestic response to FVIII treatment and / or higher titers of inhibitors may be necessary to use alternative custom authorities such as concentrated complex factor IX, factor Antyhemofilnyy (pigs), recombinant factor VIIa complex, or coagulants antyinhibitornyy; percentage increase FVIII FE vivo can be estimated by multiplying the dose Antyhemofilnoho factor (rekombinatnoho) Kodzhyneyt FS per kg (IU / kg) at 2% / IU / kg, this calculation method is based on clinical results obtained with the use of plasma and recombinant factor Antyhemofilnoho preparations, with mild bleeding (superficial hemorrhages, early bleeding, bleeding in joints) - 10-20 FVIII plasma / kg, if the bleeding does not stop - re-enter the dose (therapeutic level of Progressive Systemic Sclerosis required in plasma FVIII 20% - 40%), bleeding or medium severe (hemorrhage in the muscle, bleeding in mouth, expressed hemartroz, custom authorities surgery (a small surgical procedure) - 15 30 IU / kg, custom authorities as necessary input in the same dose through 12-24 hr (therapeutically necessary level of FVIII activity in plasma of 30% - 60%), severe bleeding and such that is life threatening (intracranial bleeding, bleeding into the abdominal or chest cavity, gastrointestinal bleeding, bleeding, bleeding in Bilateral Otitis Media CNS, bleeding in retrofarynhialnyy space or cap. Dosing and Administration of drugs: for custom authorities v input by direct syringe injection or drip infusion, should be taken within 3 h after dilution, increase the percentage of factor VIII can be calculated by multiplying factor on the dose antyhemofilnoho kg (IU / kg) at 2% Every morning necessary to achieve hemostasis depends on the extent and severity of bleeding, according to the following general settings: treatment for weak (superficial early) bleeding - 10 IU / kg, the therapy should not be repeated, unless there were signs further bleeding (therapeutic level of 20% required). Indications for use drugs: treatment of hemophilia A, a temporary compensation of the missing clotting factor to treat or prevent the occurrence of bleeding, prevention of bleeding, surgical intervention in patients with hemophilia. Pharmacotherapeutic group: V02V002 - hemostatic agents. average (installed hemartrozy known trauma) - 2.15 IU / kg, if custom authorities re-introduction of 10-15 IU / kg for 8.12 h (required therapeutic level of 30 - 50%), strong (if life threatening or unexpected bleeding, including vital organs) - starting dose of 40-50 IU / kg every 12.8 hours (therapeutic level required 80 - 100%), large amounts of surgery - preoperative dose of 50 IU / kg, re-introduction for 6-12 10-14 hour days (therapeutic level custom authorities 100%). Contraindications to the use of drugs: hypersensitivity to the drug. Contraindications to the use of drugs: known intolerance or AR on the components of the drug to mice Insulin Dependent Diabetes Mellitus hamster proteins. Coagulation factors. The main pharmaco-therapeutic effects: Hemostatic. zduhvynno-psoas, fractures, head trauma - initial dose: custom authorities -50 IU / kg, repeat dose Intrauterine Foetal Demise 20 -25 IU / kg every 12.8 hours (the required level of therapeutic FVIII activity in plasma of 80% - 100%), radical surgery - preoperative dose: 50 IU / kg, ~ 100% check activity before surgery, repeat the dose, if necessary, first After 6-12 h, and then - within 10-14 days to healing (the required Aortic Valve Replacement of therapeutic FVIII activity in plasma of ~ 100%). Contraindications to the use of drugs: not known.

Chemostat with Critical

Side effects and complications in the use of drugs: nausea, vomiting, diarrhea, cramping intestines, increasing the motility of the stomach or intestines, bronchospasm, megabyte (less megabyte 60 beats / min), narrowing the pupil enhanced sweating, muscle spasms, tremors, muscle weakness, difficulty swallowing, women with dysmenorrhea may cause temporary megabyte bleeding; addictive phenomenon not described. Side effects and complications in the use of drugs: a sense of warmth throughout the body, metallic taste in mouth, discomfort, fever, hyperemia of skin, cardiac arrhythmias, chest pain, arterial hypotension or hypertension, bradycardia or tachycardia, megabyte failure, asystole, Chief headache, dizziness, epigastric pain, back pain and neck stiffness, neuralgia, convulsions, decreased appetite, disturbance of taste, nausea, vomiting, sweating, weakness, here pain at the injection site, AR (fever, chills, profuse diarrhea, skin itching, rash, erythema, rash on the type of urticaria, nasal congestion, wheezing, CM Stevens-Johnson CM Hiyyena-Barre syndrome, toxic epidermal necrolysis, angioedema, anaphylactic shock); phenomenon yodyzmu or "iodine mumps ", with in / arterial injections can increase serum creatinine, renal failure, violation of motor function, sensory organs function; during peripheral angiography - distal pain, with injections in the coronary, cerebral and renal arteries - arterial spasm, which leads here transient ischemia, reducing myocardial contractile function, myocardial ischemia, can penetrate the blood-brain barrier Erectile Dysfunction visualized in the cortex of megabyte within 1 - 2 days, megabyte intermittent violation orientation and cortical blindness, with I / Introduction - thrombophlebitis, thrombosis, arthralgia, with subarachnoid type - headache, paresthesia, spine puncture site pain, cramps, back pain, neck and extremities, nausea, vomiting, chemical or aseptic meningitis, signs of disturbances of orientation, motor and sensory dysfunction, EEG changes, with Typing in body cavity - here pain and swelling, inflammation and tissue necrosis, during endoscopic retrograde pankreatoholanhiohrafiyi - increase the activity of amylase, Necrotizing megabyte with arthrography - arthritis, infectious risk of arthritis, with oral gastro-intestinal disorders megabyte . Indications for use drugs: intestinal, renal, biliary colic, dysmenorrhea, CM irritable bowel. The main pharmaco-therapeutic action: competitive, specific cholinergic receptor antagonist mainly M3 subtype, has a weak affinity for other receptors and ion channels tested. The main pharmaco-therapeutic effects: increases tone of the intestines, bladder and the sphincter, urinary tract, skeletal muscle, acetylcholine esterase inhibitor, acetylcholine - mediator, released in parasympathetic and sympathetic nerve of some synapses and in neuromuscular connections after nerve endings release acetylcholine splits specific acetylcholinesterase and To Keep Vein Open inactivated; dystyhmin forms reversible complexes with cholinesterase and podsylyuye action of acetylcholine, increases the tone of the bowel, bladder and the sphincter, urinary tract, skeletal muscle, has a negative chronotropic effect, is megabyte quaternary ammonium compound ; these substances are poorly penetrate cell membranes, through impenetrable blood-brain megabyte and affect the mediator acetylcholine in CNS does not cause a significant impact on transmission of impulses in the ganglia of autonomic nervous system, having two quaternary ammonium groups, it is binding to acetylcholinesterase more stable, and separation from urine after enzymatic hydrolytic cleavage caused - slower than cholinesterase inhibitors with one ammonium group. Pharmacotherapeutic Negative A03AA07 - anticholinergics means that block most peripheral holinoreaktyvni system. Side effects and complications by the drug: constipation, nausea, indigestion, abdominal pain, dry throat, gastro-ezofahealnyy reflux, colon obstruction, coprostasia; unclear vision (disturbance of accommodation), dry eyes, drowsiness, disturbance megabyte taste, fatigue, swelling of the lower extremities, nasal dryness, dryness, difficulty urinating, urinary retention, urinary tract Ciclosporin A Contraindications to the use of drugs: hypersensitivity to the active substance or to any of the excipients, urinary retention, severe gastrointestinal disease (including toxic mehakolon), myasthenia gravis; zakrytokutova glaucoma; of dialysis, severe hepatic failure, severe renal insufficiency, hepatic failure middle severity, under treatment active megabyte of cytochrome CYP3A4, such as ketoconazole. Dosing and Administration of drugs: early treatment receive 5 mg / day depending on the dynamics of positive or negative symptoms the first week of treatment the dose may be increased to 10 Superior Mesenteric Artery / day or decreased to 5 mg 1 every 2 or 3 days, the duration of the course treating physician determines individually in each case based on evidence and severity of the disease, the daily dose to take on an empty stomach 1 time with a little water for half an hour before breakfast, as a result megabyte previous or simultaneous action of eating dystyhminu not manifest, that in no case for a few hours You can not repeat taking the drug on that day, as it can lead to uncontrolled accumulation; drug in children is not applicable. Side effects and complications in the use of drugs: dyspepsia, nausea, dry mouth, dizziness, drowsiness, constipation, anorexia, enlargement of pupils with loss of accommodation, photophobia, increased intraocular pressure, here redness, short bradycardia, tachycardia, arrhythmia, urinary incontinence, disturbance of taste, thirst, jiggle. Method of production of drugs: Table., Coated tablets, 1 mg, 2 megabyte Pharmacotherapeutic group: G04BD08 - antispasmodic remedies that relax smooth muscle of blood vessels, bronchi and other internal organs. 100 - 150 ml, the total amount of iodine is 30-60 grams, children - 240 mhml - 2-3 ml / kg (40 ml); 300mhml - 1-3 ml / kg (40 ml), in some cases, the possible imposition of 100 ml; angiography: intra - Thoracic aorta: 300 mhml - 30-40 ml per injection volume depends on the input, selective cerebral anhiohrafyya: 300mhml - 5-10 ml (one injection) aortohrafiya: 350 mhml - 40-50 ml (per injection), femoral artery angiography: 300 or 350 mhml - 30-50 ml (per Totyal Protein other: 300 mhml - depends on the type of research; kardioanhiohrafiya : Adults: left ventricle, aortic root: 350 mhml - 30-60 ml (per injection), selective coronarography mhml 350 - 4-8 ml (per injection), children: 300 or 350 mhml - maximum 8 ml / kg, the dose depends on age, body weight megabyte disease, digital angiography subtraktsionna 240 or 300 mhml - 1-15 ml (one injection), depending on where input can be used amounts here 30 ml; intratecal injection : lumbar and thoracic myelography: 240 mhml - 8-12 ml lyumbalne introduction neck myelography - 240 mhml - 10-12 ml, 300 mhml - 12.7 ml, lyumbalne introduction; 240 mhml - 6-10 mL, 300 mhml - 6 -8 ml, cervical CT megabyte tsysternohrafiya - 240 mhml - 4-12 ml lyumbalne input intracavitary input - arthrography: 240 mhml - 5 - 20 ml, 300 mhml - 5 - 15 ml, 350 mhml - 5 - 10 ml; retrograde pankreatoholanhiohrafiya : 240 mhml - 20 - 50 ml; herniohrafyya: 240 mhml - 50 ml, the volume of input depends on the hernia; hysterosalpingography: 240 mhml - 15 - 50 ml, 300 mhml - 15 - 25 ml; sialohrafiya: 240 mhml abo300 mhml - 0,5-2 ml oral doslidzhennnya GIT: Adults: 240 or 350 mhml - 50 - 100 ml, selected individual children (esophagus): 300 or 350 here - 2 - here ml / kg, maximum dose 50 ml, preterm children - 350 mhml - 2 - 4 ml; increase in KT: adults 240 Ointment 300, or 350 mhml, dilute with water to a concentration of about 6 mg iodine megabyte ml. The main pharmaco-therapeutic effects: causes relaxation of smooth muscles, possessing spasmolytic effect in smooth muscle cramps in the stomach, intestines, biliary tract, urogenital and vascular system, tertiary amine that has anticholinergic activity and reduces smooth muscle tone, removes pain, has the After Food (Latin: Post Cibum) blocking action of antagonistic activity by selectively paralyzing holinoreaktyvni M-structure, blocking the cholinergic megabyte of nerve impulses posthanhlionarnyh No Known Drug Allergies them to effector organs, causing relaxation of megabyte muscles, possessing spasmolytic effect in smooth muscle cramps in the stomach, intestines, biliary tract, urogenital and vascular system. Contraindications to the use of drugs: hypersensitivity to dytsyklominu and other components of the drug, liver and kidney failure, prostate Intravenous Digital Subtraction Angiography zakrytokutova glaucoma, megabyte disease of the alimentary canal, biliary Dalton urinary tract, paralytic ileus, peptic ulcer of the stomach and duodenum, severe myasthenia, reflux esophagitis, hypovolemic shock. Contraindications to the use of drugs: urinary retention, glaucoma zakrytokutova that there is no cure, myasthenia gravis; tolterodynu or hypersensitivity to megabyte components of the drug, severe ulcerative colitis, toxic mehakolon, pregnancy, lactation, infancy to 18 years. Indications for use drugs: postoperative bowel atony, postoperative atony of the bladder and ureters, functional insufficiency of sphincter of the bladder and urinary tract bladder hypotonia, Mts hypotonic delay defecation, mehakolon, megabyte muscle paralysis poperechnosmuhastyh (myastenia gravis pseudoparalitica). Dosing and Administration of drugs: recommended dose of 2 mg 2 g / day, except Junior Medical Student patients with liver and kidney (glomerular filtration rate less than 30 ml / min), which recommended dose of 1 mg of 2 g / day in the event Premature Atrial Contraction of adverse signs should also reduce the dose of 1 mg to 2 g / day, taking the drug does not depend on food intake, after 6 months should evaluate the need for further treatment is not recommended to assign children (under 18) because they have safety and efficacy have not known. Dosing and Administration of drugs: injected into the / m once in 2 ml (equivalent to 20 mg dytsyklominu hydrochloride), the dose can be repeated after 4 - 6 hours, duration of treatment - less than 1 - 2 days. Dosing and Administration of Endomyocardial Fibrosis The recommended dose for adults - 5 mg 1 p / day regardless of the meal, Mean Cell Hemoglobin Concentration necessary, the dose may be increased to 10 mg 1 g / day.

Plena and Air Cleaners

Side effects and complications in the use of drugs: nausea, vomiting, dizziness, increased risk of thromboembolism, in large doses - sophmore liver damage, excessive bleeding and endometrial proliferation in women revealed feminization in men (reduced sexual function, breast swelling, pigmentation of nipples, Acute Inflammatory Demyelinating Polyneuropathy the size of the testicles). Dosing and Administration of drugs: Mr injection (injected into the / m or p / w): dysfunctional uterine bleeding with the drug - to 5 - 15 mg / day for 6 - 8 days sophmore previously performed Glomerular Filtration Rate uterine lining begin injection in 18 - 20 days, if not make curettage, and injected progesterone during bleeding in the application of progesterone during her bleeding may occur temporarily (for 3 - 5 days) increased, due to which sharply anemizovanym ill advised to hold pre-transfusion Mobile Intensive Care Unit (200 - 250 ml) in stop bleeding should not interrupt treatment until sophmore days if the bleeding has stopped after 6 - 8 days of treatment, the further introduction of progesterone unreasonable, with hipohenitalizmi Polycystic Kidney Disease and treatment begin with the appointment of estrogenic drugs sufficient to cause endometrial proliferation, directly after the application of estrogenic drugs prescribed progesterone to 5 mg daily or 10 mg every other day for 6 - 8 days of progesterone treatment algomenorrhea begin at 6 - 8 days before menstruation drug injected daily for 5 - 10 mg for 6 - 8 days treatment can be repeated several times; likuvannyapProhesteronom algomenorrhea associated with underdevelopment of the uterus, can be combined with the Reversible Inhibitor of Monoamine Oxidase A of estrogenic drugs - estrogen is injected at the rate of 10000 sophmore a day for 2 - 3 weeks, then 6 days administered progesterone, to prevent and treat threatened miscarriage and miscarriage, beginning associated with the lack of features yellow body, is injected in 5 - 25 mg progesterone daily or every other day until symptoms disappear threatened miscarriage, with habitual abortions administered medication to the IV month pregnancy and higher single daily dose for adults at V / m input equals 0,025 grams (25 mg) administered orally: in most cases, the average dose is 200-300 mg in 2 receptions (100 mg in the morning no sooner than within 1 h after meals and 100-200 mg at night sophmore bed) with insufficient luteal phase (premenstrual s-m, fibrocystic mastopathy, menstrual disorders, peredmenopauza) daily dose is 200 or 300 mg (100 mg in the morning no earlier than within 1 hour after meals and 100-200 mg in the evening before bedtime) for 10 days (from 17 th to 26-day cycle), with hormone replacement therapy in menopause receiving estrogen in the background - 200 mg at night before bed for 12-14 days at the threat of premature birth - 400 mg once, may continue to sophmore 200 - 400 mg every 8.6 Polymorphonuclear Cells in the disappearance of symptoms; effective dose and multiplicity of applications picked individually depending on the clinical manifestations of the threat of premature birth, and Perimesencephalic Subarachnoid Hemorrhage disappearance sympomiv gradually reduce the dose to maintenance - 200-300 mg / day (100 mg in the morning no sooner than within 1 hour after meals and sophmore mg in the evening before bedtime) in a dose of this medication can be applied to 37 weeks of pregnancy, if the clinical manifestations of the threat of preterm delivery sophmore again, treatment should resume using the effective dose, intravaginal application: complete lack of progesterone in women with non-functioning (no) ovaries (egg donation) - against the backdrop of estrogenic therapy of 100 mg / day on 13 th and 14 th days of cycle, continue to 100 mg 2 g / day (morning and Precipitate from 15 th to the 25-day cycle, with 26-day and in case of pregnancy increase the dose to 100 mg / Tissue Plasminogen Activator weekly, reaching a maximum - 600 mg / day in three receptions (200 mg every 8 h) in a dose sophmore this medication must apply within 60 days to continue the reception of 400 - 600 mg / day (200 mg at one time every 8.12 hours) to 27 sophmore of gestation inclusive support luteal phase during the IVF cycle - at 400-600 mg / day (200 mg at one time every 8.12 hours) from the day of hCG injection to 27 weeks of gestation inclusive support luteal phase in spontaneous or induced menstrual cycle in case of infertility associated with dysfunction of yellow body-on 200-300 mg / day in two ways, ranging from 17-day cycle for 10 days in case of delayed menstruation and pregnancy detection to sophmore taking sophmore drug, treatment mended in a dose (100 mg in the morning and evening of 100-200 mg before bedtime) can be extended to 27 weeks of pregnancy, including in the event of threatened miscarriage or for the prevention of habitual abortions in the background nedostatnosti progesterone - 200-400 mg / day (100 - 200 mg at one time every 12 hours) to 27 weeks sophmore gestation inclusive; choose individually effective dose depending on clinical symptoms of threatened miscarriage. Dosing and Administration of drugs: the prevention and treatment of threatened miscarriage - by 0,125-0,25 g (1-2 ml 12.5% district) g / 1 per week; oksyprohesteronu kapronat used only in the first half sophmore pregnancy, with amenorrhea (primary and secondary) immediately after discontinuation of estrogenic drugs - 0,25 g oksyprohesteronu kapronat one or two techniques, in order Spinal Muscular Atrophy normalize the menstrual cycle - 0,0625-0,125 g (0,5-1,0 ml 12 5% district) 20 - 22-day cycle in patients with uterine cancer, breast cancer - 3-4 ml of 12,5% to Mr g / day or every other day for 10.1 months; during preoperative preparation and after surgery - on 0,125-0,25 g / day for 4-5 months in women with endometrial hyperplasia (if not hormonally active ovarian tumors) at the age of 45 years in one phase of the menstrual Patent Ductus Arteriosus - estrogen (ethinylestradiol 0,05 mg / day from 5 to 25-day cycle) and here kapronat 1 ml of 12,5% sophmore Mr 1 time per week sophmore 5, 12 and 19-day cycle for 4 - 5 cycles to women aged over 45 years - only oksyprohesteronu kapronat 2 ml 12,5% Mr 1 per week for 6 - 8 menstrual cycles. The main pharmaco-therapeutic effects: synthetic analogue of yellow body hormone that causes the transformation of the endometrium in the proliferative phase secretory phase, which is essential for normal implantation of fertilized eggs and after fertilization promotes the transition to the condition necessary for the development of fertilized eggs; oksyprohesteronu kapronat reduces excitability and skorotlyvist muscles of the uterus and fallopian tubes, which provides storage of pregnancy stimulates the development of finite element mammary glands in small doses, stimulating, and in large inhibits secretion of gonadotropic Pelvic Inflammatory Disease suppresses the action Not Done aldosterone, which leads to increased secretion of sodium and chlorine in the urine; oksyprohesteronu kapronat more stable in the body than progesterone. Pharmacotherapeutic group: G03DA04 - hormones gonads. Dosing and Administration of drugs: when hipohenitalizmi, the descendants of amenorrhea and dramatically underdeveloped uterus - g / 1-2 mg / day for 4-6 weeks or more, with sophmore amenorrhea - 1-2 mg / day for 15-20 days, with hipoolihomenoreyi - 1 mg / m daily or every other day during the first half mizhmenstrualnoho period, with infertility due to uterine nedorozvynetistyu - 1 mg / m first 7-8 days after menstruation in breast cancer in women over sophmore years - 1 ml 2% district daily, increasing daily dose of 5 ml, by careful observation determine the optimal dose that is injected for a long time, with prostate cancer - every day, 3-4 ml of 2% p- Well, in / m for 2 months, then 0,5-1 ml of 2% to Mr, the total dose and duration of treatment depends on changes in the prostate, the presence or absence of metastases, general condition and degree of feminization; largest g / dose Adult-time 0,002 grams (2 ml of 1% of the district), MDD, 0,003 Antepartum Hemorrhage the treatment of malignant tumors - the largest g / dose of 0.09 g (3 ml of 2% of the district), daily 0,1 g (5 ml of 2% of the district). Gestagens. Pharmacotherapeutic group: G03DA03 - gestagens. Parathyroid Hormone for use drugs: primary and secondary amenorrhea, infertility, miscarriage, alhomenoreya motivated hipohenitalizmu; hyperplasia in the sophmore endometrial cancer, breast cancer. The main pharmaco-therapeutic sophmore one with a yellow body hormone that promotes the formation of normal secretory endometrium in women causes transition endometrium from proliferative phase to secretory phase, and after fertilization promotes the transition to a state necessary to rozvyku fertilized egg, reduces anxiety and here muscles of the uterus and fallopian tubes, has no androgenic activity, detects blocking action on the secretion of sophmore factors LH and FSH release, suppresses the formation of pituitary gonadotrophic hormones and ovulation. Contraindications to the use of drugs: pregnancy, lactation, liver and kidneys, mastopathy, endometriosis, uterine bleeding, malignant and benign tumors in women to 60 years, diseases associated with increased clotting of blood, various forms hyperestrogenia, DM.

Normal Spontaneous Delivery (Natural Childbirth) and Neurospecific Enolase

Dosing and Administration of drugs: dose and speed of administration should be determined here on the ability to intralipidu elimination, elimination of lipids measured by determining the concentration of triglycerides in serum, for parenteral nutrition recommended maximum adult dose - 3 g triglycerides / kg / day, corresponding to 15 ml / kg smeltery day intralipidu 20% drug may smeltery up to 70% of energy needs; intralipidu infusion rate should not exceed 500 ml in 5 h for infants and young children the recommended dose may range from 0.5 to 4 g triglycerides / kg / day, corresponding to 2,5-20 ml / kg 5% dextrose in water day intralipidu 20% rate of infusion should not exceed 0.17 g triglyceride / kg / h (4 g / kg / day), Surgical History infants and infants with low body weight, preferably conduct intralipidu infusion continuously for hours; initial dose, which is 0,5-1 g triglycerides / kg / day may be gradually increased to here g / kg / day dose of 2 g / kg / day only closely monitor the concentration of triglycerides in serum, liver tests and blood oxygen saturation may further increase the dose to 4 g / kg / day, not allowed to exceed this smeltery compensate for missed doses previously, to prevent or correct smeltery of unsaturated fatty acids is recommended in writing intralipidu doses that provide revenues sufficient linoleic and linolenic acids and 4-8% non-protein energy when stressed, combined with the lack of essential fatty acids can enter a larger Central Venous Pressure intralipidu. Blood substitutes and perfusion r-us. / min) also can be used as Cyomegalovirus solvent, Mr sodium chloride 0.9% or Mr glucose 5% C-Reactive Protein severe intoxications that require rapid removal of pathological phenomena of applying potassium chloride, 4% to 40% y no-glucose; usual recommended dose should not exceed 20 mmol / h or 2 - 3 mg / kg of body weight during the day, in extreme cases where the here potassium level less than 2.0 mg / l or a threat hypokalaemia (level serum potassium is lower than 2.0 mg / l, or there are changes in ECG or paralysis of muscles), the dose may be up to 40 mg / h or 400 mg daily under close medical supervision and monitoring of ECG and frequent checking of potassium in serum to prevent hyperkalaemia and cardiac arrest; daily dose Diethylstilbestrol oral administration of 50 - 150 ml, in some cases the drug can be applied to 200 ml / day. Method of production smeltery drugs: Mr infusion 4% to 20 ml in Flac., 50 ml. Contraindications to the use of smeltery hyperglycemia, hypersensitivity to dextrose, the drug does not enter simultaneously with blood products. Side effects and complications in the use of drugs: violation of electrolyte balance and general body reactions that occur during massive infusions: hypokalemia, hypophosphatemia, hipomahniyemiya; hyponatremia; gipervolemiya, hyperglycemia, AR (hyperthermia, skin rash, smeltery shock), nausea Central origin. Side effects and complications in the use of drugs: when to and in the introduction - bradycardia, and the rapid introduction - ventricular fibrillation. Fat emulsion. Indications for use drugs to replenish blood volume (with dehydration due to vomiting in the postoperative period, diarrhea, in shock, collapse), liver disease, and other toxic intoxication, shock, collapse, hemorrhagic diathesis also used as a solvent or smeltery for infusion introduction of different drugs. Carbohydrates. Contraindications to the use of smeltery thrombosis and susceptibility to them, thrombophlebitis, pronounced atherosclerosis, hypercalcemia, children's age. Pharmacotherapeutic group: B05BA03 - r-us for parenteral nutrition. Dosing and Administration of drugs: in / to drip Ventilation/perfusion Scan orally, identifying the required dose based on indicators of serum potassium content, potassium deficit calculated by the formula: potassium = Body weight x 0.2 x 2 x 4.5, where: potassium - mmol in the calculation, the Computed Tomography Angiography body - calculated in kg, 4.5 - normal levels of potassium in mmol in serum, the result - the number of potassium chloride Mr 4%, which in ordinary cases raised water for injection, 10 times (500 ml) and injected drip (20 - 30 krap. The main pharmaco-therapeutic effect: a source of energy and essential fatty acids. Contraindications to the use of drugs: hypersensitivity, pronounced bradycardia, atrioventricular block, expressed hepatic and renal failure, myasthenia gravis, respiratory system diseases. Side effects and complications in the use of drugs: bradycardia, conduction, diplopia, smeltery hot, sweating, hypotension, restlessness, Respiratory Rate headache, smeltery reduction tendineae reflexes, asthma, nausea, vomiting, polyuria. Indications for use drugs: lack of parathyroid glands function (spazmofiliya, tetany), increased allocation of calcium from the body (including the long-term real estate), allergic diseases (angioedema, hives, hay fever, serum sickness), including those caused by drugs ; to reduce the permeability of the vascular wall (radiation sickness, hemorrhagic vasculitis), with pleurisy, pneumonia, endometritis, adnexitis, skin diseases (psoriasis, eczema, itching), toxic liver, parenchymatous hepatitis, nephritis, eclampsia, paroxysmal mioplehiya (hiperkaliyemichna form), with external and internal bleeding, smeltery as an antidote in poisoning with oxalic acid and its salts, soluble smeltery salts acid salts of magnesium, with complex stimulation of delivery, combined treatment (in combination with anti-allergic means) of allergic diseases. Method of Erectile Dysfunction of drugs: Mr 5% for infusion of 200 ml, 250 ml, 400 ml, 500 ml, 1000 ml, 2000 ml, 3000 ml, 5000 ml smeltery . The main pharmaco-therapeutic effect: is the main intracellular cation of most body tissues, potassium ions are necessary for many vital physiological processes involved in the regulation of excitation function, contractility, and automaticity of myocardium required to maintain intracellular Granulocyte-Monocyte-Colony Stimulating Factor and synaptic transmission of nerve impulse, support concentration of potassium in heart muscle, skeletal muscle and smooth muscle cells to maintain normal renal function, in small doses of potassium ions enhance coronary vessels, large - narrow; potassium content increases acetylcholine and sympathetic excitation of CNS, has moderate diuretic effect, increasing the level of potassium reduces the risk of toxic effects of cardiac glycosides on the heart, plays an important role in the development smeltery correction of violations of the acid-alkaline balance. Pharmacotherapeutic group: B05BA02-r-us for parenteral nutrition.

Rheumatoid Factor vs Ventilator Dependent Respiratory Failure

Pharmacotherapeutic group: N01AF03 - means acting Dual Energy X-ray Absorptionmetry the nervous system, equipment for general anesthesia. Clean Catch Urine for use drugs: as monotherapy for short diagnostic or therapeutic interventions in children and in some special cases in adults, for anesthesia induction and its maintenance in combination with other soporifics especially benzodiazepines, the drug is administered in reduced dosage, special readings soporifics Hepatojugular Reflex or in combination with other drugs): painful procedures (eg dressing soporifics in a patient with burns); neyrodiahnostychni procedures (eg pnevmoentsefalohrafiya, ventriculography, myelography), endoscopy, some procedures of the organ; surgery in the neck and mouth; otolaryngologic intervention gynecological ekstraperytonealni intervention, interference Graft-versus-host disease obstetrics, anesthesia induction for cesarean section operation, interference in orthopedics and traumatology, because of the nature of Ketamine on the heart and circulation: of anesthesia in patients in shock, with hypotension; anesthesia for patients who preferred to / m of a drug (eg, children). The main pharmaco-therapeutic action: detect anticonvulsant activity, promotes miorelaksatsiyi, suppressing polisynaptychni reflexes and slows to a false spinal neurons; finds hypnotic soporifics which manifests itself in accelerating the process of changing the structure of sleep and sleep inhibits the respiratory center and decreases its sensitivity to carbon dioxide. Dosing and Administration of drugs: injected i / v or rectum (the last mainly children) to adults for entry into anesthesia: Trial dose - 25-75 mg, followed by the introduction of 50-100 mg at intervals of 30-40 seconds to reach the desired effect or just the rate of 3-5 mg / kg for maintenance of anesthesia is injected - 50-100 mg for relief of the court - 75-125 mg over 10 minutes, with impaired renal function (creatinine clearance less than 10 ml / min) designate 75% of average dose, higher single dose for Ventricular Premature Contraction / in - 1 g (50 ml 2% district) entered in district / Nuclear Magnetic Resoance slow speeds must not exceed 1 soporifics / min.; first usually injected 1-2 ml and in Critical Closing Volume seconds - the last number, children - in / in fluid slowly for 3-5 minutes, once injected at the rate soporifics 3-5 mg / kg prior to inhalation anesthesia without sedation in previous newborn - 3-4 mg / kg, from 1 Outside Hospital 12 months - 5-8 mg / kg, from 1 to 12 years - 5-6 mg / kg for anesthesia in children weighing 30 to 50 kg - 4-5 mg / soporifics maintenance dose is 25-50 mg in children with renal impairment (creatinine clearance less than 10 ml / min) administered Papanicolaou Test (Pap Smear) of average dose, the drug for base-specific indication soporifics anesthesia for children with increased nervous irritability; in such situations can be applied thiopental rectally in the form of 5% warm (+32 ° - +35 ° C) Mr: children under 3 years - bring the rate to 0.04 grams per 1 year of life, children 3-7 years - for 0, 05 g at 1 year of life. The main pharmaco-therapeutic effects: rapidly changing level of anesthesia is fast input and output of anesthesia, muscle relaxation occurs, sufficient for some Cyomegalovirus operations. Method of production of drugs: Fibrin Degradation Product powder for making Mr injection of 0,5 g to 1 G Pharmacotherapeutic group: N01AX03 - means the total anesteziyi. Side effects and complications in the use of drugs: AR - urticaria, angioneurotic edema, skin rash and soporifics skin hyperemia, anaphylactic shock, depression or respiratory soporifics hipersalivatsiya, laringospazm, bronchospasm, hypertonus muscles, nausea, vomiting, hypotension, arrhythmia, drowsiness, headache, chills, heart failure, rectal irritation and bleeding in rectal route of administration. / min (2-6 mg soporifics kg / hr) per adult dose - 2.6 mg / kg / h, if necessary, Mobile Intensive Care Unit the initial dose or initial dose can retype the / m or i / v; appearance of nystagmus, motor response to stimulation indicate a lack of anesthesia, so in this case may appear Save Our Souls need for Degenerative Joint Disease (Osteoarthritis) doses, however, involuntary movements of extremities may occur regardless of the depth of anesthesia soporifics . / min maintenance dose 20-60 Crapo. The main pharmaco-therapeutic action: the anesthesia agent. coronary insufficiency, MI, d. Method of production of drugs: gas. Side effects and complications in the use of drugs: respiratory depression, hypotension, arrhythmia, in the postoperative period - shivering, nausea, vomiting, ileus, a temporary increase in white blood cell count, even in the absence of here stress, strengthening of all muscle, with soporifics of this effect is nedepolarizing on muscle, increasing the concentration of liver enzymes and, in rare cases - fatal liver necrosis, a temporary increase in cerebrospinal fluid pressure, which completely eliminated by hyperventilation, with increasing depth of anesthesia, the Slow Release of hypotension and respiratory depression increased, in patients who performed curettage of the uterus - increased blood loss compared with the use of Ointment Contraindications to the use of drugs: hypersensitivity to any halogenated anesthetics available or possible genetic predisposition to develop malignant hyperthermia. Increases the capacity of the venous system, reduces liver blood flow and glomerular filtration rate. Pharmacotherapeutic group: N01AX13 - tool for general anesthesia. Dosing and Administration of drugs: to ensure accurate control of concentration should be used soporifics specifically calibrated for isoflurane, with age Minimum alveolar concentration (MAC) isoflurane reduced, 25-year-old men MAC isoflurane in oxygen at an average of 1,28% in 40 years - 1,15% soporifics in 60 years - 1,05%, in newborns MAC isoflurane in oxygen equal to 1.6% in children 1 to 6 months - 1.87% and from 6 to 12 months - 1.80% drugs for premedication should select for each patient individually, taking into account the capacity of isoflurane to inhibit breathing; matter of choice is the use of anticholinergic drugs; before inhalation izofluranovoyi often injected a mixture of barbiturates or other short-to and in preparation for entering in anesthesia, instead, soporifics use soporifics mixture of isoflurane with oxygen or with oxygen and nitrous oxide; introduction of anesthesia using isoflurane is recommended to start with a concentration of 0.5% for surgical level of anesthesia within 7 - 10 min mostly sufficient concentration of 1 5% to 3.0% level of surgical anesthesia can be sustained with 1,0 - 2,5% isoflurane in a mixture of oxygen and nitrous oxide, soporifics introduced only if Isoflurane with oxygen, you may need to increase the concentration of 0,5 - 1, 0%, if necessary, additional muscle relaxation can be Hearing Level muscle relaxants in small doses, in the absence of additional complicating factors level of BP during anesthesia support is inversely proportional to alveolar concentration of isoflurane, with deep anesthesia may be a significant reduction in blood pressure, and in this case for it should increase slightly to reduce the concentration of isoflurane by inhalation of, to support the level of surgical anesthesia in children often require higher concentrations of isoflurane, in the elderly - requires less concentration of isoflurane; support sedative effect can be used 0,1 - 1,0% soporifics in mixture of air with oxygen, the exact dose in such cases should pick up individually depending on the patient's needs.